

OIP-120  
 11 Nov 02 2008  
 11 Nov 02 2008

10583068 - GAU: 1648

PTO/SB/08 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031  
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 10

**Complete if Known**

Application Number	10/583068
Filing Date	June 15, 2006
First Named Inventor	Lisa Ng Fong Poh,
Art Unit	Not assigned
Examiner Name	Not assigned
Attorney Docket Number	033946-1401

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	US 2003/0148985 A1	08/07/2003	Morrissey et al.	
	A2	6,740,665 B1	05/25/2004	Murali et al.	

**UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	A3	WO 96/18738	06/20/1996	Sugen, Inc.		
	A4	WO 01/92655 A1	12/06/2001	C-Power AB		
	A5	WO 98/45421	10/15/1998	The University Court of the University of Glasgow		
	A6	WO 96/23879	08/08/1996	Terrapin Technologies, Inc.		
	A7	WO 03/029462 A1	04/10/2003	Pieris Proteolab AG		
	A8	WO 03/035621 A1	05/01/2003	The Research Foundation of St. University of New York		
	A9	WO 2004/029199 A1	04/08/2004	Smithkline Beecham Corporation		
	A10	CA 2378871	01/18/2001	Scii Proteins GmbH, DE		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	A11	Backe et al., Crystallization, MicroPIXE and Preliminary Crystallographic Analysis of the Complex Between the Third KH Domain of the hnRNP K and Single-Stranded DNA <i>Acta Crystallogr D Biol Crystallogr</i> 60 (4), 2004, 784-787	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DLMR\_290584.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.L./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/583068
Filing Date	June 15, 2006
First Named Inventor	Lisa Ng Fong Poh
Art Unit	Not assigned
Examiner Name	Not assigned
Attorney Docket Number	033946-1401

(use as many sheets as necessary)

Sheet 2 of 10

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A12	Bean, The use of Alternative Medicine in the Treatment of Hepatitis C, <i>Am Clin Lab</i> 21 (5), 2002, 25-27 (abstract)	
	A13	Beste et al., Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. <i>Proc. Natl. Acad. Sci. USA</i> 96, 1999, 1898-1903	
	A14	Bomsztyk et al., hnRNP K : One Protein Multiple Processes, <i>Bioessays</i> 26 (6), 2004, 629-638	
	A15	Braddock et al., Molecular Basis of Sequence-Specific Single-Stranded DNA Recognition by KH Domains : Solution Structure of a Complex Between hnRNP K KH3 and Single-Stranded DNA, <i>EMBO J</i> 21 (13), 2002, 3476-3485	
	A16	Bartenschlager, Unexpected Host Range of Hepatitis C Virus Replicons, <i>Hepatology</i> 39 (3), 2004, 835-838	
	A17	Brekke and Loset, New Technologies in Therapeutic Antibody Development, <i>Curr Opin Pharmacol</i> 3 (5), 2003, 544-550	
	A18	Burd and Dreyfuss, Conserved Structures and Diversity of Functions of RNA-Binding Proteins, <i>Science</i> 265, 1994, 615-621	
	A19	Cai et al., LRH-1/hB1F and HNF1 Synergistically Up-Regulate Hepatitis B Virus Gene Transcription and DNA Replication <i>Cell Res</i> 13 (6), 2003, 451-8 (abstract)	
	A20	Chen et al., Altered Antigenicities of Hepatitis B Virus Surface Antigen Carrying Mutations Outside The Common "a" Determinant, <i>Am. J. Gastroenterol.</i> 95, 2000, 1098	
	A21	Ching et al., Viral Hepatitis B, <i>Lancet</i> 362(9401), 2003, 2089-2094	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			<b>Application Number</b>	10/583068
			<b>Filing Date</b>	June 15, 2006
			<b>First Named Inventor</b>	Lisa Ng Fong Poh
			<b>Art Unit</b>	Not assigned
			<b>Examiner Name</b>	Not assigned
(use as many sheets as necessary)			<b>Attorney Docket Number</b>	033946-1401
<b>Sheet</b>	3	of	10	

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>§</sup>
	A22	Cohen SA et al., Potential Future Clinical Applications For the GPIIb/IIIa Antagonist, Abciximab in Thrombosis, Vascular and Oncological Indications, <i>Pathol Oncol Res.</i> 6 (3), 2000, 163-174	
	A23	Cooksley, The Importance and Benefits of Hepatitis A Prevention in Chronic Liver Disease Patients, <i>J Gastroenterol Hepatol.</i> 19 (Suppl 1), 2004, S17-20	
	A24	Debets R et al., IL-18 Receptors, Their Role in Ligand Binding and Function : Anti-IL-1RAcPL Antibody, a Potent Antagonist of IL-181, <i>J Immunol.</i> 165 (9), 2000, 4950-4956	
	A25	Dejgaard et al., Identification, Molecular cloning, Expression and Chromosome Mapping of a Family of Transformation Upregulated hnRNP-K Proteins Derived by Alternative Splicing, <i>J. Mol. Biol.</i> 236 (1), 1994, 33-48	
	A26	Ferenc, Peginterferon Alfa-2a (40KD) (Pegasy) For the Treatment of Patients with Chronic Hepatitis C, <i>Int J Clin Pract.</i> 57 (7), 2003, 610-615 (abstract)	
	A27	Gadaleta, et al., Isolation of a 25-kDa Protein Binding to a Curved DNA Upstream the Origin of the L Strand Replication in the Rat Mitochondrial Genome, <i>J. Biol. Chem.</i> 271, 1996, 13537	
	A28	Goetzi, et al., An IgM-kappa Rat Monoclonal Antibody Specific for the Type 1 Sphingosine 1-Phosphate g Protein-Coupled Receptor With Antagonist and Agonist Activities, <i>Immunol Lett.</i> 93 (1), 2004, 63-69	

<b>Examiner Signature</b>	<b>Date Considered</b>
---------------------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-3199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/583068		
		Filing Date	June 15, 2006		
		First Named Inventor	Lisa Ng Fong Poh		
		Art Unit	Not assigned		
		Examiner Name	Not assigned		
Sheet	4	of	10	Attorney Docket Number	033946-1401

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A29	Halasz et al., GB Virus C/Hepatitis G Virus, <i>Scand J Infect Dis.</i> 33 (8), 2001, 572-580	
	A30	Hino, TTV, A New Human Virus With Single Stranded Circular DNA Genome, <i>Rev Med Virol.</i> 12 (3), 2002, 151-158	
	A31	Holt et al., Domain Antibodies: Proteins For Therapy, <i>Trends Biotechnol.</i> 21 (11), 2003, 484-490	
	A32	Hryniewicz-Jankowska A et al., Ankyrins, Multifunctional Proteins Involved in Many Cellular Pathways, <i>Folia Histochem. Cytobiol.</i> 40, 2002, 239-249 (abstract)	
	A33	Hsieh, et al., Hepatitis C Virus Core Protein Interacts With Heterogeneous Nuclear Ribonucleoprotein K, <i>J Biol Chem.</i> 273 (28), 1998, 17651-17659	
	A34	Janmaat and Giaccone, Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, <i>Oncologist</i> 8 (6), 2003, 576-586	
	A35	Köhler & Milstein, Continuous Cultures of fused Cells Secreting Antibody of Predefined Specificity, <i>Nature</i> 256, 1975, 495-497 (abstract)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind's Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/583068
Filing Date	June 15, 2006
First Named Inventor	Lisa Ng Fong Poh
Art Unit	Not assigned
Examiner Name	Not assigned
Attorney Docket Number	033946-1401

(use as many sheets as necessary)

Sheet 5 of 10

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	P <sup>2</sup>
	A36	Lai and Ware, Hepatitis C Virus Core Protein: Possible Roles in Viral Pathogenesis, <i>Curr Top Microbiol Immunol</i> 242, 2000, 117-134 (abstract)	
	A37	Lee et al., Expression of Small Interfering RNAs Targeted Against HIV-1 rev Transcripts in Human Cells, <i>Nature Biotechnology</i> 20 (5) 2002, 500-505	
	A38	Lelliott, et al., Lamin Expression in Human Adipose Cells in Relation to Anatomical Site and Differentiation State, <i>Journal of Clinical Endocrinology</i> 87, 2002, 728-734	
	A39	Li, et al., Heterogeneous Nuclear Ribonucleoprotein A1 Binds to the Transcription-Regulatory Region of Mouse Hepatitis Virus RNA, <i>Proc Natl Acad Sci USA</i> 94 (18), 1997, 9544-9549	
	A40	Li et al., Morphine Enhances Hepatitis C Virus (HCV) Replicon Expression, <i>Am J Pathol</i> 163 (3), 2003, 1167-75	
	A41	Mandal et al., Growth Factors Regulate Heterogeneous Nuclear Ribonucleoprotein K Expression and Function, <i>J Biol Chem</i> 276 (13), 2001, 9699-9704	
	A42	Marcellin et al., Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B, <i>N Engl J Med</i> 351 (12), 2004, 1205-1217	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			<b>Complete if Known</b>		
			<b>Application Number</b>	10/583068	
			<b>Filing Date</b>	June 15, 2006	
			<b>First Named Inventor</b>	Lisa Ng Fong Poh	
			<b>Art Unit</b>	Not assigned	
			<b>Examiner Name</b>	Not assigned	
			<b>Attorney Docket Number</b>	033946-1401	
Sheet	6	of	10		

(use as many sheets as necessary)

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	7 <sup>6</sup>
	A43	Martell et al., Structural Analysis of Hepatitis C RNA Genome Using DNA Microarrays, <i>Nucleic Acids Research</i> 32 (11), 2004, e 90	
	A44	Mulrooney, Quantitive Detection of Hepadnavirus-Infected Lymphoid Cells by In Situ PCR Combined with Flow Cytometry: Implications for the Study of Occult Virus Persistence, Michalak TI, <i>J Virol</i> 77 (2), 2003, 970-979	
	A45	Ng et al., Host Heterogeneous Ribonucleoprotein K (hnRNP K) as a Potential target to Suppress Hepatitis B Virus Replications, <i>PLoS Med.</i> 2 (7), 2005, e163	
	A46	Ong and Younossi, Managing The Hematologic Side Effects of Antiviral Therapy for Chronic Hepatitis C: Anemia, Neutropenia, and Thrombocytopenia, <i>Cleve Clin J Med.</i> 71, Suppl 3, 2004, S17-21	
	A47	Ostrowski et al., Insulin Alters Heterogeneous Nuclear Ribonucleoprotein K Protein Binding to DNA and RNA, <i>Proc. Natl. Acad. Sci. USA</i> 98 (16), 2001, 9044-9049	
	A48	Papatheodoridis and Hadziyannis, Review Article: Current Management of Chronic Hepatitis B, <i>Aliment Pharmacol Ther.</i> 19 (1), 2004, 25-37	
	A49	Pazin and Williams, Triggering Signaling Cascades by Receptor Tyrosine Kinases, <i>Trends in Biochemical Sciences</i> 17 (10), 1992, 374-378	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 10

**Complete if Known**

Application Number	10/583068
Filing Date	June 15, 2006
First Named Inventor	Lisa Ng Fong Poh
Art Unit	Not assigned
Examiner Name	Not assigned
Attorney, Docket Number	033946-1401

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A50	Plank et al., The Magnetofection Method : Using Magnetic Force to Enhance Gene Delivery, <i>Biol Chem.</i> 384 (5), 2003, 737-747	
	A51	Poynard et al., Viral Hepatitis C, <i>Lancet</i> 362(9401), 2003, 2095-2100	
	A52	Pyne et al., Receptor tyrosine Kinase-GPCR Signal Complexes, <i>Biochem Soc Trans.</i> 31 (6), 2003, 1220-1225	
	A53	Reddy et al., Use of Peginterferon Alfa-2a (40 KD) (Pegasys®) for the Treatment of Hepatitis C, <i>Advanced Drug Delivery Reviews</i> 54 (4), 2002, 571-586	
	A54	Reichard et al., Randomised, Double-Blind, Placebo-Controlled Trial of Interferon $\alpha$ -2b With and Without Ribavirin for Chronic Hepatitis C, <i>Lancet</i> 351 (9096), 1998, 83-87	
	A55	Rippe et al., Techniques to Measure Nucleic Acid-Protein Binding and Specificity: Nuclear Extract Preparations, DNase I Footprinting, and Mobility Shift Assays, <i>Methods Mol Biol.</i> 160, 2001, 459-479 (abstract)	
	A56	Roche and Samuel, Evolving Strategies to Prevent HBV Recurrence, <i>Liver Transpl.</i> 10 Suppl, 2004, S74	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WFO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			<b>Application Number</b>	10/583068
			<b>Filing Date</b>	June 15, 2006
			<b>First Named Inventor</b>	Lisa Ng Fong Poh
			<b>Art Unit</b>	Not assigned
			<b>Examiner Name</b>	Not assigned
(use as many sheets as necessary)			<b>Attorney Docket Number</b>	033946-1401
Sheet	8	of	10	

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A57	Sioud, Ribozyme-and siRNA-Mediated mRNA Degradation: A General Introduction, <i>Methods Mol Biol.</i> 252, 2004, 1-8 (abstract)	
	A58	Skerra, Engineered Protein Scaffolds for Molecular Recognition, <i>J. Mol. Recognit.</i> 13, 2000, 167-187	
	A59	Stapleton, GB Virus Type C/Hepatitis G Virus, <i>Semin Liver Dis.</i> 23 (2), 2003, 137-148 (abstract)	
	A60	Steen and Jensen, Analysis of Protein-Mucleic Acid Interactions by Protochemical Cross-Linking and Mass Spectrometry, <i>Mass Spectrom Rev.</i> 21 (3), 2002, 163-182	
	A61	Su and Yee, Regulation of Hepatitis B Virus Gene Expression by its two Enhancers, <i>Proc Natl Acad Sci U S A</i> 89 (7), 1992, 2708-2712	
	A62	Takahashi, et al., Hepatitis B Virus Genomic Sequence in the Circulation of Hepatocellular Carcinoma Patients: Comparative Analysis of 40 Full-Length Isolates, <i>Archives of Virology</i> , 143, 1998, 2313-2326	
	A63	Tay et al., Identification and Cloning of a Novel Heterogeneous Nuclear Ribonucleoprotein C-Like Protein That Functions as a Transcriptional Activator of the Hepatitis B Virus Enhancer II, <i>J. Virol.</i> , 66 (12), 1992, 6841-6848	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 9 of 10

**Complete if Known**

Application Number	10/583068
Filing Date	June 15, 2006
First Named Inventor	Lisa Ng Fong Poh
Art Unit	Not assigned
Examiner Name	Not assigned
Attorney Docket Number	033946-1401

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A64	Thompson et al, Recent Advances in Fluorescence Correlation Spectroscopy, <i>Curr Opin Struct Biol.</i> 12 (5), 2002, 634-641	
	A65	Uchida et al., Silent Hepatitis B Virus Mutants are Responsible for Non-A, Non-B, Non-C, Non-E Hepatitis, <i>Microbiol Immunol</i> 38, 1994, 281-285 (abstract)	
	A66	Velazquez-Campoy et al., Protein-Protein Interactions Methods and Applications, <i>Methods Mol Biol.</i> 261, 2004, 35-54 (abstract)	
	A67	Visintin et al., Intercellular Antibodies for Proteomics, <i>J Immunol Methods</i> 290 (1-2), 2004, 135-153	
	A68	Wang and Zhuang, Hepatitis E: An Overview and Recent Advances in Vaccine Research, <i>World J Gastroenterol.</i> 10 (15), 2004, 2157-2162	
	A69	Wang et al., A New Enhancer Element, ENII, Identified in the X Gene of Hepatitis B Virus, <i>J Virol.</i> 64 No. 8), 1990, 3977-3981	
	A70	Weiner et al., Rapid and Reproducible Quantification of Hepatitis C Virus cDNA by Fluorescence Correlation Spectroscopy <i>Digestion</i> 61 (2), 2000, 84-89 (abstract)	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/583068
		<b>Filing Date</b>	June 15, 2006
		<b>First Named Inventor</b>	Lisa Ng Fong Poh
		<b>Art Unit</b>	Not assigned
		<b>Examiner Name</b>	Not assigned
(use as many sheets as necessary)		<b>Attorney Docket Number</b>	033946-1401
<b>Sheet</b>	10	<b>of</b>	10

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A71	Weiss et al., The HBV-Producing Cell Line HepG2-4A5: A New in vitro System for Studying the Regulation of HBV Replication and for Screening Anti-Hepatitis B Virus Drugs, <i>Virology</i> 216, 1996, 214-218	
	A72	Yee, A Liver-Specific Enhancer in the Core Promoter Region of Human Hepatitis B Virus, <i>Science</i> 246, 1989, 658-661	
	A73	Yi and Lemon, 3' Nontranslated RNA Signals Required for Replication of Hepatitis C Virus RNA, <i>J Virol.</i> 77 (6), 2003, 3557-3568	
	A74	Yuh and Ting, The Genome of Hepatitis B Virus Contains a Second Enhancer: Cooperation of Two Elements Within This Enhancer is Required for its Function, <i>J Virol.</i> 64 (9), 1990, 4281-4287	
	A75	Zhou et al., Detection of Hepatitis B Virus by Piezoelectric Biosensor, <i>Journal of Pharmaceutical and Biomedical Analysis</i> 27 (1), 2002, 341-345	
	A76	Zhu et al., Replication of Hepatitis C Virus Subgenomes in Nonhepatic Epithelial and Mouse Hepatoma Cells, <i>J Virol.</i> 77 (17), 2003, 9204-9210	

<b>Examiner Signature</b>	/Zachariah Lucas/	<b>Date Considered</b>	02/22/2010
---------------------------	-------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.